After FDA Rejected MDMA Therapy: Where Psychedelic-Assisted Treatment Stands in 2026
- FDA rejected Lykos Therapeutics' NDA for MDMA-assisted therapy for PTSD in August 2025, citing concerns about trial methodology, blinding, and safety monitoring — the first psychedelic therapy to reach FDA review
- Lykos announced plans for additional trials, but timeline for re-submission is 2-3+ years. State-level access programmes (Oregon, Colorado) continue independently of FDA decisions
- Psilocybin research continues: EPIsoDE trial (JAMA Psychiatry, March 2026) showed mixed results for treatment-resistant depression. COMPASS Pathways preparing Phase 3
- The regulatory landscape is fragmenting: federal rejection + state legalisation + international trials creating a patchwork of access and evidence
The FDA rejection of MDMA-assisted therapy in August 2025 was not the end of psychedelic-assisted treatment. It was the end of the fast track. The science continues, the states continue, and the international trials continue — but the pathway to federal approval is now measured in years, not months.
What the FDA actually said
The rejection was not about efficacy. The FDA's concerns were methodological: blinding integrity (can you really blind participants to whether they received MDMA?), functional unblinding leading to expectancy effects, and adequacy of long-term safety monitoring. These are the same concerns raised by the EPIsoDE psilocybin trial — they are structural to psychedelic research, not specific to one company.
The state-federal split
Oregon's psilocybin service centres opened in 2023. Colorado followed. These programmes operate under state law, independent of FDA approval. A patient in Portland can legally access psilocybin-assisted therapy. A patient in New York cannot. This creates a two-tier system where access depends on geography, not evidence.
For clinicians, this fragmentation creates practical questions: Can you refer patients to Oregon? If your patient travels for legal psilocybin, what is your role in preparation and integration? If a patient uses psilocybin recreationally and brings the experience to therapy, how do you work with it clinically?
Where the evidence stands
The evidence is mixed and incomplete. MDMA showed efficacy in Phase 3 trials but with methodological concerns. Psilocybin shows signals in depression but missed its primary endpoint in the largest European trial. Ketamine is the only psychedelic-adjacent substance with FDA approval (Spravato/esketamine for treatment-resistant depression) — and its long-term effectiveness data is still accumulating.
For your practice
Do not recommend psychedelic therapy to patients — the evidence does not support clinical recommendation yet. Do prepare for patients who will seek it anyway: discuss what the evidence shows and does not show, help with preparation and integration if they pursue legal access, and maintain clinical neutrality between enthusiasm and dismissal.
After the FDA rejected MDMA therapy and the largest psilocybin trial showed mixed results, the evidence for psychedelic-assisted treatment is promising but incomplete — clinicians should inform, not recommend.
Rapidly evolving field — regulatory and research landscape may change within months. State-level access creates inconsistent quality standards. Long-term safety data for all psychedelic therapies remains insufficient.